Abu-Bakar Zafar, MD
Ophthalmology · Urbana, ILNPI 1194015016
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.2% of the total across 62 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $295, 5.9 times the $50 reported in 2019. That places this record below the midpoint for ophthalmology clinicians in IL, where the typical reported total is $1,164.
Across 62 payments — averaging $20.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$221
- Alcon$136
- Bausch & Lomb Americas Inc.$124
- Johnson & Johnson Surgical Vision, Inc.$120
- Mallinckrodt Hospital Products Inc.$116
- Harrow Eye, LLC$101
- plus $435 from 13 others
Across 5 payments — averaging $3295.73 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Oyster Point Pharma, Inc.$16K
What the payments were for
- Food & beverage$1,14291%
- Education$1119%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 14 | $221 |
| Alcon | 7 | $136 |
| Bausch & Lomb Americas Inc. | 7 | $124 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $120 |
| Mallinckrodt Hospital Products Inc. | 2 | $116 |
| Harrow Eye, LLC | 4 | $101 |
| Tarsus Pharmaceuticals, Inc. | 4 | $99 |
| AbbVie(2 entities) | 5 | $92 |
| Dompe US, Inc. | 3 | $41 |
| Glaukos Corporation | 2 | $33 |
| Astellas Pharma US Inc | 1 | $30 |
| Genentech USA, Inc. | 1 | $29 |
| Amgen | 1 | $25 |
| Sun Pharmaceutical Industries Inc. | 1 | $17 |
| Biotissue Holdings Inc. | 1 | $16 |
| Aerie Pharmaceuticals, Inc. | 1 | $15 |
| Kala Pharmaceuticals, Inc. | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
| Sight Sciences, Inc. | 1 | $12 |
How this compares
$1,253 in reported general payments places this provider in the 50th percentile of 773 ophthalmology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 56 | $1,791,359 |
| XiidraLifitegrast | 207 | $154,943 |
| Prednisolone Acetate | 1,010 | $45,282 |
| Ketorolac Tromethamine | 642 | $24,909 |
| Cyclosporine | 65 | $20,716 |
| RestasisCyclosporine | 19 | $16,499 |
| Restasis MultidoseCyclosporine | 28 | $16,046 |
| MoxifloxacinMoxifloxacin Hcl | 788 | $13,971 |
| TyrvayaVarenicline Tartrate | 14 | $9,221 |
| Loteprednol Etabonate | 64 | $8,815 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 27 | $6,038 |
| Fluorometholone | 81 | $5,438 |
| ValacyclovirValacyclovir Hcl | 155 | $4,687 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 14 | $3,915 |
| Latanoprost | 287 | $3,624 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $41 | $1,791,35956 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $124 | $157,960219 claims |
| AbbVieRestasis, Restasis Multidose | $92 | $32,54547 claims |
| AlconSimbrinza | $136 | $3,91514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 773 ophthalmology providers in Illinois.
Other ophthalmology in Urbana
- Leanne LabriolaUrbana$43K
- Seenu HariprasadChicago$2.3M
- Lisa NijmSpringfield$1.7M
- Kathleen MornoNorth Riverside$1.2M
- Veeral ShethOak Forest$716K
- James KatzDes Plaines$642K
- Mitchell JacksonLake Villa$584K
- David LubeckHomewood$575K
- Parag MajmudarHighland Park$451K
- Daniel OwensLombard$343K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.